Alnylam Pharmaceuticals Inc
F:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
F:DUL
|
US |
|
O
|
Omnicom Group Inc
XMUN:OCN
|
US |
|
Danone SA
F:BSND
|
FR |
|
N
|
Novartis AG
XBER:NOT
|
CH |
|
T
|
Telekom Austria AG
XMUN:TA1
|
AT |
|
I
|
Ingevec SA
SGO:INGEVEC
|
CL |
|
R
|
Regions Financial Corp
F:RN7
|
US |
|
J
|
Juventus FC SpA
F:JUVE
|
IT |
|
R
|
Relx PLC
F:RDED
|
UK |
|
K
|
KeyCorp
DUS:KEY
|
US |
|
M
|
Meiji Holdings Co Ltd
DUS:3M0
|
JP |
|
D
|
Dental Corporation PCL
SET:D
|
TH |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 383.46 EUR with a low forecast of 201 EUR and a high forecast of 501.14 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
383.46
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 383.46 EUR with a low forecast of 201 EUR and a high forecast of 501.14 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 8 years is 36%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Net Income over the next 8 years is 41%.
